Skip to content
value.today
Crescent Biopharma, Inc. logo

Crescent Biopharma, Inc.

CBIO
$195 Mlast known market cap, Jan 2024 — no current value
Compare
World rank
—
no current market cap
Revenue
$11 M
For year ending December-2025
Net income
$-154 M
-1420.1% margin
SEC filing
Employees
44
As of December 31, 2025
value.today research

Crescent Biopharma, Inc. in brief

Crescent Biopharma, Inc. is a listed company in the Biotechnology industry, based in Maryland, USA. It was founded in 2003. Its last known market value was $195 M (January 2024); there is no current figure. In the year to December 2025 it had sales of $11 M and a net loss of $154 M. It employs about 44 people. Its largest business segments by sales in 2025 were Reportable (100%). Its shares trade under the symbol CBIO (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Crescent Biopharma, Inc.

We were incorporated under the laws of the State of Delaware in 2003. Our company, formerly known as GlycoMimetics, Inc., is a biotechnology company that is the result of a reverse recapitalization transaction with a private company named Crescent Biopharma, Inc.. Prior to the reverse recapitalization transaction, Pre-Merger Crescent was established and incorporated under the laws of the state of Delaware on September 19, 2024. On June 16, 2025, in connection with the reverse recapitalization transaction with Pre-Merger Crescent, we changed our jurisdiction of incorporation from the state of Delaware to the Cayman Islands pursuant to a plan of conversion.

Crescent Biopharma, Inc. timeline

6 events, 2003–2025
  1. 2003
  2. 🏁
    · approximate
    Founded
  3. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  4. 2014
  5. 🔔
    · approximate
    Initial public offering on Nasdaq
  6. 2025
  7. 💰
    Record revenue of $11 million
    FY2025, the highest of the 5 years on record.
  8. 💰
    Record net income of $0 million
    FY2025, the highest profit of the 3 years on record.
  9. ✎
    Renamed Crescent Biopharma, Inc.
    Formerly Glycomimetics Inc.

Events of Crescent Biopharma, Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$60 M$121 M$181 M$242 M20202021202220232024

World rank over time

▼ down 2,676 places since 2020
2020-01-01: #15357#15,35720202021-01-01: #15932#15,93220212022-01-07: #24685#24,68520222022-12-25: #20710#20,71020222023-07-30: #21411#21,41120232024-01-05: #18033#18,0332024

Rank in USA: #3,149 (Jan 2020) · #3,319 (Jan 2021) · #4,662 (Jan 2022) · #4,130 (Dec 2022) · #4,181 (Jul 2023) · #3,268 (Jan 2024)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
—
Free cash flow yield
—
Net margin
-1420.1%
Operating margin
-1408.0%
Return on equity
-75.8%
Liabilities / assets
15.5%
Revenue growth
+108300.0%
R&D / revenue
1273.9%
Revenue per employee
$246 K
Profit per employee
$-3.5 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue —, net income $-48M—FY18Fiscal year ending Dec 2019: revenue —, net income $-58M—FY19Fiscal year ending Dec 2020: revenue $10M, net income $-51M$10MFY20Fiscal year ending Dec 2021: revenue $1M, net income $-63M$1MFY21Fiscal year ending Dec 2022: revenue $0M, net income $-47M$0MFY22Fiscal year ending Dec 2023: revenue $0M, net income $-37M$0MFY23Fiscal year ending Dec 2024: revenue —, net income $-38M—FY24Fiscal year ending Dec 2025: revenue $11M, net income $-154M$11MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$11M—$-153M$-154M-1420.1%
Dec 2024——$-40M$-38M—
Dec 2023$0M-87.5%$-39M$-37M-369000.0%
Dec 2022$0M-93.1%$-47M$-47M-58362.5%
Dec 2021$1M-88.6%$-63M$-63M-5468.1%
Dec 2020$10M—$-52M$-51M-502.3%
Dec 2019——$-61M$-58M—
Dec 2018——$-52M$-48M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-72M$1M$-72M——
Dec 2024$-31M$0M$-31M$-0.59—
Dec 2023$-35M$0M$-35M$-0.58—
Dec 2022$-46M$0M$-47M$-0.89—
Dec 2021$-57M$0M$-58M$-1.23—
Dec 2020$-39M$0M$-39M$-1.12—
Dec 2019$-52M$0M$-52M$-1.34—
Dec 2018$-43M$0M$-43M$-1.18—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024: revenue —, net income $-18M—Dec ’24Three months to Mar 2025: revenue —, net income $-15M—Mar ’25Three months to Jun 2025: revenue —, net income $-22M—Jun ’25Three months to Sep 2025: revenue —, net income $-25M—Sep ’25Three months to Dec 2025: revenue —, net income $-23M—Dec ’25Three months to Mar 2026: revenue $1M, net income $-23M$1MMar ’26Three months to Jun 2026: revenue —, net income $-25M—Jun ’26Three months to Sep 2026: revenue $3M, net income $-38M$3MSep ’26

Latest quarter to Sep 2026: revenue $3M, net income $-38M. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Crescent Biopharma, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$11 M
Operating income
$-153 M
Net income
$-154 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$240 M
Total liabilities
$37 M
Total equity
$203 M

As of December-2025

Top 100 institutional investors in Crescent Biopharma, Inc.#

As of Sep 30, 2026
105 institutions held 40.4 M shares (more than all shares outstanding: lent and sub-advised shares are reported by more than one filer) on Sep 30, 2026. The ten largest hold 67.9%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Crescent Biopharma, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1FMR LLC5,904,998+1,771,484 (+42.86%)15.18%$86 MNov 10, 2026
2Fairmount Funds Management LLC3,601,316+853,450 (+31.06%)9.26%$53 MNov 16, 2026
3BVF Inc/il3,093,590+344,827 (+12.54%)7.95%$45 MNov 16, 2026
4Vestal Point Capital, LP3,000,000+1,370,000 (+84.05%)7.71%$44 MNov 16, 2026
5BlackRock, Inc.2,138,232+866,470 (+68.13%)5.50%$31 MNov 13, 2026
6Venrock Adviser, LLC2,133,734+158 (+0.01%)5.49%$31 MNov 16, 2026
7Fcpm III Services B.V.2,022,679+344,827 (+20.55%)5.20%$30 MNov 16, 2026
8Opaleye Management Inc.1,645,984+326,633 (+24.76%)4.23%$24 MNov 16, 2026
9Balyasny Asset Management L.P.1,611,958-50,959 (-3.06%)4.14%$24 MNov 16, 2026
10Vanguard Capital Management LLC1,268,637+500,882 (+65.24%)3.26%$19 MNov 13, 2026
11Tang Capital Management LLC1,160,0000 (0.00%)2.98%$17 MNov 16, 2026
12Jennison Associates LLC1,102,081+723,574 (+191.17%)2.83%$16 MNov 16, 2026
13Blackstone Inc.1,060,281+997,634 (+1592.47%)2.73%$15 MNov 16, 2026
14Logos Global Management LP850,000-1,050,000 (-55.26%)2.19%$12 MNov 16, 2026
15State Street Corp843,070+527,483 (+167.14%)2.17%$12 MNov 12, 2026
16Geode Capital Management, LLC735,089+350,513 (+91.14%)1.89%$11 MNov 6, 2026
17Perceptive Advisors LLC706,942+500,000 (+241.61%)1.82%$10 MNov 16, 2026
18Ameriprise Financial Inc680,736+378,168 (+124.99%)1.75%$10 MNov 16, 2026
19Adage Capital Partners GP, L.L.C.500,000New1.29%$7 MNov 16, 2026
20Siren, L.L.C.400,000New1.03%$6 MNov 12, 2026
21RTW Investments, LP372,8560 (0.00%)0.96%$5 MNov 16, 2026
22NEXTBio Capital Management LP372,8560 (0.00%)0.96%$5 MNov 13, 2026
23Remedium Capital Partners, LLC361,2500 (0.00%)0.93%$5 MNov 13, 2026
24Squadron Capital Management LLC350,000New0.90%$5 MNov 16, 2026
25Citadel Advisors LLC349,656New0.90%$5 MNov 16, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Crescent Biopharma, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Vanguard Portfolio Management LLC287,397+98,594 (+52.22%)0.74%$4 MNov 13, 2026
27Sphera Funds Management LTD.279,718New0.72%$4 MNov 16, 2026
28Woodline Partners LP269,535+175,047 (+185.26%)0.69%$4 MNov 16, 2026
29ADAR1 Capital Management, LLC231,328+213,053 (+1165.82%)0.59%$3 MNov 16, 2026
30Northern Trust Corp230,395+91,617 (+66.02%)0.59%$3 MNov 16, 2026
31Goldman Sachs Group Inc227,258New0.58%$3 MNov 16, 2026
32Two Sigma Investments, LP211,284+24,410 (+13.06%)0.54%$3 MNov 16, 2026
33Vanguard Fiduciary Trust Co208,839+133,614 (+177.62%)0.54%$3 MNov 13, 2026
34UBS Group AG205,794+30,612 (+17.47%)0.53%$3 MNov 10, 2026
35Sectoral Asset Management Inc167,600+46,300 (+38.17%)0.43%$2 MNov 13, 2026
36Ikarian Capital, LLC150,061New0.39%$2 MNov 16, 2026
37Nuveen, LLC144,663+97,034 (+203.73%)0.37%$2 MNov 10, 2026
38Marshall Wace, LLP131,409-82,891 (-38.68%)0.34%$2 MNov 13, 2026
39Seven Grand Managers, LLC100,000New0.26%$1 MNov 16, 2026
40Charles Schwab Investment Management Inc93,663+43,405 (+86.36%)0.24%$1 MNov 16, 2026
41Bank Of America Corp /de/90,646+64,825 (+251.06%)0.23%$1 MNov 16, 2026
42Millennium Management LLC84,896-318,963 (-78.98%)0.22%$1 MNov 16, 2026
43XTX Topco Ltd80,064+69,500 (+657.89%)0.21%$1 MNov 16, 2026
44Algert Global LLC75,957New0.20%$1 MNov 17, 2026
45Burkehill Global Management, LP74,0000 (0.00%)0.19%$1 MNov 16, 2026
46Wellington Management Group LLP73,086+58,486 (+400.59%)0.19%$1 MNov 16, 2026
47Bank of New York Mellon Corp67,826+22,048 (+48.16%)0.17%$1 MNov 5, 2026
48Susquehanna International Group, LLP55,725New0.14%$1 MNov 16, 2026
49Boothbay Fund Management, LLC42,794New0.11%$1 MNov 16, 2026
50Quadrature Capital Ltd41,175New0.11%$1 MNov 13, 2026
51Schonfeld Strategic Advisors LLC32,349New0.08%$0 MNov 16, 2026
52Price T Rowe Associates Inc /MD/32,326-243,255 (-88.27%)0.08%$0 MNov 16, 2026
53Rhumbline Advisers31,145+5,658 (+22.20%)0.08%$0 MNov 10, 2026
54Engineers Gate Manager LP28,640New0.07%$0 MNov 16, 2026
55Man Group plc26,760New0.07%$0 MNov 16, 2026
56Vanguard Global Advisers, LLC25,171+22,457 (+827.45%)0.06%$0 MNov 13, 2026
57Moore Capital Management, LP25,0000 (0.00%)0.06%$0 MNov 16, 2026
58Persistent Asset Partners Ltd24,932+13,964 (+127.32%)0.06%$0 MNov 13, 2026
59Morgan Stanley22,492+4,794 (+27.09%)0.06%$0 MNov 13, 2026
60Prudential Financial Inc21,032New0.05%$0 MNov 16, 2026
61Quantinno Capital Management LP20,983New0.05%$0 MNov 13, 2026
62Soros Fund Management LLC20,000New0.05%$0 MNov 13, 2026
63Corient Private Wealth LP19,610New0.05%$0 MNov 16, 2026
64Virtus Investment Advisers, LLC17,708-550 (-3.01%)0.05%$0 MNov 12, 2026
65Barclays PLC17,625+13,163 (+295.00%)0.05%$0 MNov 6, 2026
66BNP Paribas Financial Markets17,015+13,712 (+415.14%)0.04%$0 MNov 12, 2026
67MetLife Investment Management, LLC16,655+3,875 (+30.32%)0.04%$0 MNov 16, 2026
68MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.15,038+5,137 (+51.88%)0.04%$0 MNov 16, 2026
69Rafferty Asset Management, LLC14,435New0.04%$0 MNov 13, 2026
70Jpmorgan Chase & Co14,308+5,288 (+58.63%)0.04%$0 MNov 12, 2026
71Creative Planning11,676New0.03%$0 MNov 2, 2026
72Invesco Ltd.11,542-189 (-1.61%)0.03%$0 MNov 12, 2026
73ACT Capital Partners, L.P.11,500—0.03%$0 MNov 6, 2026
74Wells Fargo & Company/mn8,841-10,859 (-55.12%)0.02%$0 MNov 16, 2026
75Police & Firemen's Retirement System of New Jersey8,464+2,095 (+32.89%)0.02%$0 MNov 9, 2026
76New York State Common Retirement Fund7,6000 (0.00%)0.02%$0 MNov 17, 2026
77Citigroup Inc6,865-3,276 (-32.30%)0.02%$0 MNov 4, 2026
78Simplex Trading, LLC3,413New0.01%$0 MNov 4, 2026
79Legal & General Group Plc2,750+653 (+31.14%)0.01%$0 MNov 16, 2026
80Rockefeller Capital Management L.P.1,857New0.00%$0 MNov 13, 2026
81Royal Bank Of Canada1,499+818 (+120.12%)0.00%$0 MNov 16, 2026
82Employees Retirement System of Texas1,486New0.00%$0 MNov 10, 2026
83Tower Research Capital LLC (TRC)1,342-419 (-23.79%)0.00%$0 MNov 16, 2026
84Sterling Capital Management LLC960+884 (+1163.16%)0.00%$0 MOct 22, 2026
85UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC848New0.00%$0 MNov 16, 2026
86California State Teachers Retirement System2970 (0.00%)0.00%$0 MNov 13, 2026
87Parallel Advisors, LLC231-33 (-12.50%)0.00%$0 MNov 3, 2026
88Farther Finance Advisors, LLC215New0.00%$0 MOct 8, 2026
89Allworth Financial LP202+41 (+25.47%)0.00%$0 MNov 17, 2026
90GAMMA Investing LLC148New0.00%$0 MOct 8, 2026
91Caitong International Asset Management Co., Ltd103+82 (+390.48%)0.00%$0 MOct 29, 2026
92SBI Securities Co., Ltd.71+3 (+4.41%)0.00%$0 MOct 22, 2026
93Signaturefd, LLC67New0.00%$0 MOct 23, 2026
94Arax Advisory Partners56New0.00%$0 MNov 12, 2026
95Russell Investments Group, Ltd.40-1,686 (-97.68%)0.00%$0 MNov 6, 2026
96Fortitude Family Office, LLC400 (0.00%)0.00%$0 MOct 14, 2026
97Global Retirement Partners, LLC29New0.00%$0 MNov 10, 2026
98Osaic Holdings, Inc.260 (0.00%)0.00%$0 MNov 12, 2026
99Root Financial Partners, LLC26New0.00%$0 MOct 21, 2026
100EverSource Wealth Advisors, LLC23New0.00%$0 MNov 4, 2026

All 105 institutional investors, with who bought and sold →

Superinvestors holding Crescent Biopharma, Inc.

1 of the well-known investors value.today follows, from their newest Form 13F.

Mutual funds holding Crescent Biopharma, Inc.#

68 funds hold shares worth $72 M (about 10.9% of the company). Since their previous reports 54 added shares and 5 sold, buying $36 M net.
Mutual funds holding Crescent Biopharma, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.661,946$12 M1.7%<0.01%−5.3%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors516,613$9 M1.3%0.01%newJun 30, 2026
🇺🇸 Fidelity Small Cap Growth FundFidelity Management & Research Company LLC432,286$6 M1.1%0.07%newJul 31, 2026
🇺🇸 Fidelity Growth Company FundFidelity Management & Research Company LLC292,679$6 M0.75%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Advisor Biotechnology FundFidelity Management & Research Company LLC356,090$5 M0.92%0.23%+42%Jul 31, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors199,418$4 M0.51%0.02%newJun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC236,413$3 M0.61%0.01%newJul 31, 2026
🇺🇸 T. Rowe Price Health Sciences Fund, Inc.T. Rowe Price Associates, Inc.187,920$3 M0.48%0.03%−15%Jun 30, 2026
🇺🇸 Fidelity Small Cap Growth K6 FundFidelity Management & Research Company LLC221,488$3 M0.57%0.07%newJul 31, 2026
🇺🇸 Select Biotechnology PortfolioFidelity Management & Research Company LLC113,421$2 M0.29%0.04%no changeMay 31, 2026
🇺🇸 Fidelity Advisor Health Care FundFidelity Management & Research Company LLC149,413$2 M0.38%0.07%newJul 31, 2026
🇺🇸 Fidelity Growth Company K6 FundFidelity Management & Research Company LLC103,161$2 M0.27%<0.01%−1.3%May 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.83,801$2 M0.22%<0.01%+2.3%Jun 30, 2026
🇺🇸 Fidelity Series Growth Company FundFidelity Management & Research Company LLC69,195$1 M0.18%<0.01%no changeMay 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors71,187$1 M0.18%0.08%newJun 30, 2026
🇺🇸 Fidelity Small Cap Stock FundFidelity Management & Research Company LLC65,700$1 M0.17%0.07%newJul 31, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC38,989$1 M0.10%<0.01%−2.6%May 31, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.52,768$1 M0.14%0.01%newJul 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC39,685$1 M0.10%0.01%newJun 30, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC28,660$0 M0.07%0.01%newJul 31, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC22,637$0 M0.06%0.01%newJun 30, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC20,234$0 M0.05%0.02%newJun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC17,565$0 M0.05%<0.01%+47%May 31, 2026
🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust15,612$0 M0.04%0.01%+291%May 31, 2026
🇺🇸 T. Rowe Price Health Sciences PortfolioT. Rowe Price Associates, Inc.17,631$0 M0.05%0.04%no changeJun 30, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation15,700$0 M0.04%0.01%newJun 30, 2026
🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC18,969$0 M0.05%<0.01%newJul 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC12,699$0 M0.03%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC11,053$0 M0.03%<0.01%+10%May 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.11,212$0 M0.03%<0.01%−11%Jun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.10,796$0 M0.03%<0.01%+35%Jun 30, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.10,253$0 M0.03%0.01%newJun 30, 2026
🇺🇸 T. Rowe Price Extended Equity Market Index FundT. Rowe Price Associates, Inc.8,300$0 M0.02%0.01%no changeJun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC10,277$0 M0.03%<0.01%newJul 31, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.7,600$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC7,246$0 M0.02%0.01%newJun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC7,084$0 M0.02%0.01%newJun 30, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC6,023$0 M0.02%0.01%newJun 30, 2026
🇺🇸 Health Sciences TrustJohn Hancock Variable Trust Advisers LLC5,959$0 M0.02%0.04%no changeJun 30, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.5,460$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC4,778$0 M0.01%0.04%newJun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS4,633$0 M0.01%0.01%newJun 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC4,483$0 M0.01%0.01%newJun 30, 2026
🇺🇸 EQ/T.Rowe Price Health Sciences PortfolioEquitable Investment Management Group, LLC4,414$0 M0.01%0.04%no changeJun 30, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.3,396$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.3,294$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC3,209$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC3,763$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC2,837$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC2,659$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC2,400$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC2,400$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC2,741$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC2,529$0 M<0.01%0.01%newJul 31, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.2,503$0 M<0.01%<0.01%+12%Jul 31, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management1,960$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC1,944$0 M<0.01%0.02%newJun 30, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC1,726$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS1,907$0 M<0.01%0.01%newJul 31, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC1,525$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC1,862$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC974$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC751$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS907$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.545$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC454$0 M<0.01%<0.01%+64%Jun 30, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC200$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC120$0 M<0.01%<0.01%+5.3%Jul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 68 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Crescent Biopharma, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$30.6 M
2 purchases, 2 insiders
Sold, 12 months
$1.5 M
16 sales, 7 insiders
Net, 12 months
$29.1 M
open market only
Insiders on file
41
since
$18.2 M-$1.2 M$0Jun 2024: bought $83 K (3 trades), sold $0 (0 trades)Jun 24Jul 2024: bought $0 (0 trades), sold $316 K (3 trades)JulAug 2024: bought $0 (0 trades), sold $173 K (6 trades)AugDec 2025: bought $18.2 M (1 trades), sold $0 (0 trades)DecJun 2026: bought $0 (0 trades), sold $1.2 M (7 trades)JunJul 2026: bought $12.4 M (1 trades), sold $0 (0 trades)JulSep 2026: bought $0 (0 trades), sold $286 K (9 trades)Sep
Bought (open market)Sold (open market)Hover a month for the totals
Crescent Biopharma, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Joshua T. BrummChief Executive Officer, DirectorSell10b5-1 plan-7,837$16.71$131 K271,765Form 4
filed Jonathan McNeillPresident and COOSell10b5-1 plan-3,839$16.71$64 K134,588Form 4
filed Richard William ScalzoChief Financial OfficerSell10b5-1 plan-568$17.90$10 K19,730Form 4
filed Ryan LynchSee RemarksSell10b5-1 plan-240$17.90$4 K13,631Form 4
filed Jan PinkasChief Scientific OfficerSell10b5-1 plan-658$17.90$12 K21,581Form 4
filed Joshua T. BrummChief Executive Officer, DirectorSell10b5-1 plan-1,610$17.90$29 K279,602Form 4
filed Barbara Harlin BisphamSee RemarksSell10b5-1 plan-620$17.90$11 K18,710Form 4
filed Ellie Eunkyung ImChief Medical OfficerSell10b5-1 plan-623$17.90$11 K21,446Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Crescent Biopharma, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2025-06-13
6.1 M
1 days to cover
Shares sold short, last 15 reportsAll stocks →

Stock splits: 1-for-100 reverse split ; 1-for-3.33 reverse split in the period to

Trading halts

  • 2025-06-13 23:50 UTC, code D, resumed 04:00 UTC

Fails to deliver

  • : 212 shares at $0.16
  • : 4,202 shares at $0.17
  • : 18,127 shares at $0.17
  • : 162,572 shares at $0.18
  • : 360,858 shares at $0.19

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Crescent Biopharma, Inc. scorecard#

Passes 1 of the 6 checks that could be worked out. Fiscal year 2025.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth0 of 1
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
    • ✗Net income higher than five years earlier-$154 M-$154 M in fiscal 2025 against -$51 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$154 MNet income -$154 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-164.2%-164.2% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities6.6×Current ratio 6.56 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Crescent Biopharma, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Crescent Biopharma, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue11—0.00.11.210———0.0
Research and development138142028474547402423
General and administrative25181919171714119.88.7
Operating expenses163403947656261523432
Operating income−153−40−39−47−63−52−61−52−34−32
Interest expense and finance costs2.2—————————
Other non-operating income (expense)—2.22.4—————0.70.1
Income before tax−152—————————
Income tax2.0—————————
Net income including minority interests—−38−37−47−63−51−58−48−33−32
Net income attributable to shareholders−154−38−37−47−63−51−58−48−33−32
Earnings per share, basic—-0.59-0.58-0.89-1.23-1.12-1.34-1.18-1.13-1.50
Earnings per share, diluted—-0.59-0.58-0.89-1.23-1.12-1.34-1.18-1.13-1.50
Shares, weighted average (basic)—646353514643———
Shares, weighted average (diluted)—646353514643412921
Balance sheet
Cash and cash equivalents21335r42489013715821012440
Receivables180————————
Other current assets5.50.0r2.02.80.51.24.32.43.30.5
Current assets23735r44519113816321212741
Property, plant and equipment0.80—0.20.40.60.81.01.11.1
Right-of-use (leased) assets1.500.80.81.62.33.0———
Total assets24036r45529414316821512942
Accounts payable—0.30.91.02.12.11.42.72.61.6
Current liabilities369.6r6.88.91212118.88.26.3
Lease liabilities (non-current)1.200.1—0.91.92.8———
Total liabilities3747r6.98.91315149.48.97.1
Retained earnings−172−18r−456−420−373−309−258−201−152−119
Shareholders' equity203−15r38438212815420512035
Total liabilities and equity24036r45529414316821512942
Shares outstanding281.0r645452r4943433423
Cash-flow statement
Share-based compensation134.73.53.96.16.96.24.63.83.0
Cash from operating activities−72−31−35−46−57−39−52−43−30−30
Capital expenditure−0.9−0.0−0.0−0.1−0.0−0.1−0.1−0.1−0.3−0.7
Intangible assets bought−72—————————
Cash from investing activities−730.0−0.0−0.1−0.0−0.1−0.1−0.1−0.3−0.7
Shares issued0—294.21118—12811424
Cash from financing activities3230.0294.211180.412911424
Change in cash179−31−6.1−42−47−21−528684−6.8
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Crescent Biopharma, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue. Lines can overlap (a total and its parts), so they are not added up.

Business segments

  • Reportable$11 M100%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Executive pay at Crescent Biopharma, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$13.1 M
Joshua Brumm
Other top executives, average
$5.1 M
the CEO earned 2.6× this
$100 invested is now
$4
Crescent Biopharma, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Joshua Brumm$13.1 M$17.6 M$5.1 M$4
2024(1)Harout Semerjian$2.9 M$16 K$1.4 M$8
2023(1)Harout Semerjian$2.4 M$1.7 M$1.2 M$78

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Crescent Biopharma, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Auditor changedFiling
  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 2 · Auditor changed 1 · Restructuring 1 · Change in control 2 · Acquisition or sale completed 1 · Directors and officers 7 · Material agreement 5 · Agreement ended 1 · Unregistered share sale 2 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 8

Crescent Biopharma, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Directors and officersResults announced8-K
Auditor changedChange in controlAcquisition or sale completedDirectors and officersMaterial agreementShareholder rights changedBylaws or fiscal year changedResults announced8-K
Shareholder vote8-K
Material agreement8-K
Directors and officersAgreement ended8-K
Material agreement8-K
Directors and officers8-K
Delisting notice8-K
Change in controlDirectors and officersMaterial agreementUnregistered share sale8-K
RestructuringDirectors and officers8-K
Delisting notice8-K
Directors and officers8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

2 private funding rounds before listing

Private share sales · funding history

Private share sales of Crescent Biopharma, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2009$39 MNo. 2$10 to $50 million15equitySEC
Jul 2008$15 MNo. 1$10 to $50 million10equity, debt, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Layoffs at Crescent Biopharma, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
26
2024–2024
Latest
26 people
2024-07-24
Crescent Biopharma, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2024······26·····26
Crescent Biopharma, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
26 people (80% of workforce)Restructuring planSEC 8-K“In connection with the streamlined operating plan approved by the Board, on July 24, 2024, the authorized officers of the Company committed the Company to a corporate restructuring…”Filing

Source: State WARN notices and SEC 8-K item 2.05

How Crescent Biopharma, Inc. compares in Biotechnology

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Crescent Biopharma, Inc.🇺🇸$195 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Jan 5, 2024 (last known)
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 16, 2026

Figures from SEC filing, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Crescent Biopharma, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Crescent Biopharma, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Crescent Biopharma, Inc.? Suggest a correction